Skip to main content

Table 3 Metabolic and endocrine parameters at baseline (before randomization) and day 0 (immediately before chemotherapy infusion during the use of prophylactic dexamethasone)

From: The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Parameter N Baseline Median (range) Day 0 (with DEX) Median (range) In/decrease P value
Glucose (3.1-6.4 mmol/L) STF (n = 5) 5.2 (4.3-5.5) 6.8 (5.6-9.0) 0.042
Non-STF (n = 5) 4.8 (4.7-6.7) 7.0 (6.1-8.8) 0.043
Insulin (0-20 mU/L) STF (n = 5) 14.0 (2.0-40.0) 13.0 (6.0-36.0) = 0.500
Non-STF (n = 5) 2.0 (2.0-9.0) 16.0 (9.0-63.0) 0.043
Parameter N Baseline Mean (SE) Day 0 (with DEX) Mean (SE) In/decrease P value
IGF-1 (5.4-24.3 nmol/L) STF (n = 4) 23.7 (2.9) 19.6 (3.3) 0.012
Non-STF (n = 5) 17.5 (3.5) 16.8 (2.8) = 0.634
IGF-BP3 (2.2-5.8 mg/L) STF (n = 4) 5.0 (0.5) 4.2 (0.3) = 0.212
Non-STF (n = 5) 4.5 (0.2) 3.9 (0.3) = 0.122
TSH (0.3-4.8 mU/L) STF (n = 3) 1.38 (0.26) 0.61 (0.08) = 0,065
Non-STF (n = 5) 1.49 (0.14) 0.42 (0.06) 0.034
FT4 (12-22pmol/L) STF (n = 3) 15.4 (0.92) 13.9 (0.94) = 0.117
Non-STF (n = 5) 15.0 (0.54) 14.0 (0.34) = 0.149
  1. Bold value indicates that p < 0.05
  2. DEX dexamethasone, IGF-1 Insulin-like growth factor 1, IGF-BP3 insulin- like growth factor binding protein 3, TSH thyroid-stimulating hormone; FT4 free thyroxine, STF short-term fasting, SE standard error